期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 178, 期 1, 页码 72-89出版社
WILEY
DOI: 10.1111/bph.14826
关键词
-
资金
- Deutsche Forschungsgemeinschaft [SFB1213]
- British Heart Foundation [FS/18/52/33808]
- American Heart Association [33670458]
This review highlights the central role of inflammation in pulmonary arterial hypertension (PAH) and the regulation of chemokines and chemokine receptors in PAH and right ventricular remodeling. Studies have shown that pharmacological targeting of chemokines and receptors could be an effective therapeutic approach for PAH.
Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary artery remodelling leading to increased right ventricular pressure overload, which results in right heart failure and premature death. Inflammation plays a central role in the development of PAH, and the recruitment and function of immune cells are tightly regulated by chemotactic cytokines called chemokines. A number of studies have shown that the development and progression of PAH are associated with the dysregulated expression of several chemokines and chemokine receptors in the pulmonary vasculature. Moreover, some chemokines are differentially regulated in the pressure-overloaded right ventricle. Recent studies have tested the efficacy of pharmacological agents targeting several chemokines and chemokine receptors for their effects on the development of PAH, suggesting that these receptors could serve as useful therapeutic targets. In this review, we provide recent insights into the role of chemokines and chemokine receptors in PAH and RV remodelling and the opportunities and roadblocks in targeting them.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据